Alvotech And Teva File US Stelara Rival Ahead Of 2023 Expiry

Filing For AVT04 Proposed Ustekinumab Biosimilar Is Accepted By US FDA

 
• By Dave Wallace

Alvotech and marketing partner Teva have confirmed that their AVT04 proposed ustekinumab biosimilar rival to Stelara has been filed with the US FDA, ahead of a key patent expiry later this year.

Sign outside of FDA's headquarters in White Oak, MD
Alvotech’s Stelara biosimilar has been filed with the FDA • Source: Alamy

More from Biosimilars

More from Products